NCT05879874View on ClinicalTrials.gov

Prospective Evaluation of NfL as a Biomarker in ATTRv

Active, not recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Amyloidosis, Hereditary
Trial Locations (1)

Unknown

Fondazione Policlinico Gemelli IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT05879874 - Prospective Evaluation of NfL as a Biomarker in ATTRv | Biotech Hunter | Biotech Hunter